A novel lytic bacteriophage BUCT791 effectively controls multidrug-resistant Klebsiella pneumoniae in vitro and in vivo
Comparative Immunology, Microbiology and Infectious Diseases · 2026
DOI: 10.1016/j.cimid.2026.102498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comparative Immunology, Microbiology and Infectious Diseases, 2026. Verfasst von Rashid Ahmad und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 10…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Klebsiella Infections, Phage Therapy, Bacteriophages. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Acute infections caused by multidrug-resistant (MDR) Klebsiella pneumoniae immediately necessitate the development of novel therapeutic strategies. Phage therapy offers a viable alternative for combating MDR Klebsiella infections. Here, we report the isolation and comprehensive characterization of a novel lytic bacteriophage, BUCT791, recovered from hospital sewage. Phage BUCT791 exhibited a short latent period (20 min), a large burst size (∼275 PFU/cell), rapid adsorption efficiency (>90% within 15 min), and remarkable stability across a wide range of temperatures (4-50 °C) and pH values (3-12). Whole-genome sequencing revealed a 48,388 bp double-stranded DNA genome with a GC content of 50%, encoding 74 predicted open reading frames (ORFs) and lacking any virulence or antibiotic resistance genes, confirming its biosafety for therapeutic applications. Phylogenetic analysis assigned phage BUCT791 to the genus Jedunavirus (family Myoviridae) and identified it as a member of the species Klebsiella virus FZ14. In vitro assays demonstrated that BUCT791 effectively inhibited Klebsiella growth within 2 h and significantly inhibited biofilms formation. In vivo, phage treatment markedly improved Galleria mellonella larval survival from 10% to 80%. Collectively, these findings indicate that BUCT791 possesses potent antibacterial activity and represents a promising candidate for developing safe and effective phage-based therapeutics against MDR Klebsiella pneumoniae infections. IMPORTANCE: This study reports the isolation and characterization of BUCT791, a novel lytic bacteriophage active against multidrug-resistant Klebsiella pneumoniae. BUCT791 showed strong stability, efficient bacterial killing, antibiofilm activity, and improved survival in an in vivo infection model, supporting its potential as a promising alternative strategy against MDR K. pneumoniae infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address: rashidbiotech@aup.edu.pk.
- State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address: zakirbiotech33t@gmail.com.
- State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address: amnashafqat07@gmail.com.
- State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address: futurelmz123@163.com.
- State Key Laboratory of Green Biomanufacturing, BAICSM, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address: tongyigang@mail.buct.edu.cn.
Förderung
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Ahmad, R., Zakirullah, Shafqat, A., Li, M., & Tong, Y. (2026). A novel lytic bacteriophage BUCT791 effectively controls multidrug-resistant Klebsiella pneumoniae in vitro and in vivo. Comparative Immunology, Microbiology and Infectious Diseases. https://doi.org/10.1016/j.cimid.2026.102498
Vancouver
Ahmad R, Zakirullah, Shafqat A, Li M, Tong Y. A novel lytic bacteriophage BUCT791 effectively controls multidrug-resistant Klebsiella pneumoniae in vitro and in vivo. Comparative Immunology, Microbiology and Infectious Diseases. 2026. doi:10.1016/j.cimid.2026.102498
BibTeX
@article{Ahmad2026,
author = {Ahmad, Rashid and Zakirullah and Shafqat, Amna and Li, Mengzhe and Tong, Yigang},
title = {A novel lytic bacteriophage BUCT791 effectively controls multidrug-resistant Klebsiella pneumoniae in vitro and in vivo},
journal = {Comparative Immunology, Microbiology and Infectious Diseases},
year = {2026},
doi = {10.1016/j.cimid.2026.102498}
}
EUVIMED